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Chapter 5
The ‘dynamic’ marriage between 
varicella and zoster
de Boer PT, Wilschut JC, Postma MJ.





So-called dynamic modelling has explored various phenomena in infectious diseases’ epide-
miology and cost-effectiveness of interventions for control, and is increasingly becoming the 
standard and preferred approach in this area. As opposed to static modelling, dynamic model-
ling explicitly takes transmission of infectious agents into account, providing the opportunity 
to, for example, incorporate the indirect protective effect of vaccination on non-vaccinated 
individuals, i.e. herd immunity, in the analysis [1]. Often, application of a dynamic model im-
proves cost-effectiveness outcomes of infectious diseases control interventions, but in scarce 
cases detrimental effects on health, costs and cost-effectiveness might emerge. For example, 
vaccination may shift the age of infection upwards, which may be associated with increased 
severity of disease or associations with other diseases may exist [2]; reflecting additional 
effects that can be covered within a dynamic approach, next to herd protection. In this issue, 
Van Lier et al. [3] add to such insights in the context of varicella vaccination, using dynamic 
modelling. In the context of modelling herd protection and age shifts, the authors illustrate 
the potentially crucial impact of varicella vaccination on herpes zoster (HZ) disease.
Varicella zoster virus (VZV) causes chickenpox during initial infection at childhood age. 
After resolution of the disease, however, the virus remains latently present in dorsal root 
ganglion cells. In later life, it can reactivate causing HZ. Potential relationship between var-
icella vaccination and HZ disease draws on the hypothesis raised by Hope-Simpson in the 
1960s, that contacts between varicella-infected children and adults cause exogenous boosting 
of immunity against VZV in the latter, thus reducing the risk of HZ later in life [4]. In other 
words, childhood varicella vaccination, by eliminating exogenous boosting, might ultimately 
promote the risk of development of HZ in the adult population. This hypothesis is not un-
disputed, nor directly proven so far, but has received considerable attention. For instance, 
a recently published study from Ogunjimi et al. [5] modelled that childhood varicella vac-
cination might almost double HZ incidence 30 years later (for example, among parents of 
vaccinated children). Accordingly, it has been remarked – also by Van Lier et al.[1] – that a 
few generations have to pay with an increased burden of HZ for the ultimate elimination of 
VZV on the long run.
In this issue, Van Lier et al. [3] analyzed the cost-effectiveness of varicella vaccination in 
the Netherlands using dynamic modelling with the Hope-Simpson hypothesis included and 
excluded. Considering a lifetime time horizon and discounting according to the Dutch guide-
lines for pharmacoeconomic research, the authors come to a clear and consistent conclusion. 
Without the Hope-Simpson hypothesis, varicella vaccination is highly cost-effective or even 
cost-saving with major gains of quality-adjusted life years (QALYs). Inclusion of the boost-
ing hypothesis, however, results in dominance for the no varicella vaccination policy, be-
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cause varicella vaccination would result in higher costs and QALY losses due to an increase 
of HZ in the adult population.
Prior to the current study of Van Lier et al., four studies have analyzed the impact of varicella 
vaccination on HZ using dynamic modelling [6]. These studies include investigations of the 
issue for surrounding countries of the Netherlands, such as the UK [7] and Belgium [8]. Van 
Lier et al. support the overall findings from these earlier studies. Notably, similar to Van Lier 
et al. [3], these studies generally found that varicella vaccination is not cost-effective or even 
results in net QALY losses when the Hope-Simpson hypothesis was included in the mod-
elling. Generally, in these dynamic models cost-effectiveness of infant vaccination against 
varicella is driven by herd protection, related to the possible association with HZ and age 
shifts (upwards shift for varicella and potentially downwards for HZ). Potential improvement 
of the health-economic profile of varicella vaccination, suggested by the authors, includes 
targeting of vaccination to 11-year-old children after anamnesis [6].
Obviously, one solution to overcome the increase of HZ incidence among adults could be HZ 
vaccination [6-8], with highly effective vaccines being available and further developed. Van 
Lier et al. argue that HZ vaccination cannot be motivated from the perspective of its pushing 
varicella vaccination towards favourable cost-effectiveness. However, we would argue that 
HZ vaccination can be cost-effective on its own right and, on this basis, some countries, 
including the UK, have already implemented HZ vaccination. For the Netherlands, De Boer 
et al. [9] estimated the cost-effectiveness of HZ-vaccination at €29,000–36,000 per QALY 
gained, depending on the vaccination age. At a cost-effectiveness threshold of €50,000 per 
QALY, these numbers may well be considered cost-effective, in particular in view of the fact 
that even higher thresholds of €80,000 per QALY or beyond apply to oncological and orphan 
drugs [10]. Notably, the abovementioned studies for the UK [7] and Belgium [8] also found 
that combining paediatric varicella vaccination with HZ vaccination of the elderly would be 
cost-effective on the long run.
In conclusion, uncertainty on the cost-effectiveness of varicella vaccination remains, cov-
ering the full spectrum from being cost-saving to generating QALY losses. A change in this 
unsatisfactory situation through novel convincing epidemiological data cannot be expected 
on the short term. In the meanwhile, as suggested by Van Lier et al. [3], decision-making on 
implementation of infant varicella vaccination in national immunization programmes should 
weigh the various scenarios within this ‘dynamic’ marriage between varicella and zoster, re-
garding costs, benefits and likelihoods of these scenarios. Notably, combination of childhood 
varicella vaccination with HZ vaccination of the adult population may reduce the uncertainty 
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